MedTrace Logo

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

NCT04186637 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-06-05

No results posted yet for this study

Summary

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.

Conditions

Interventions

DRUG

ALPN-202

Multiple dose levels and dose regimens of ALPN-202 will be administered

Sponsors & Collaborators

  • Alpine Immune Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Allison Naumovski, Ph.D. · Alpine Immune Sciences, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-02
Primary Completion
2022-11-09
Completion
2023-02-28
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04186637 on ClinicalTrials.gov